| Maroun E Hayek, MD | |
|
1514 E Union St, Greenville, MS 38703-3248 | |
| (662) 334-6394 | |
| (662) 332-1647 |
| Full Name | Maroun E Hayek |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 28 Years |
| Location | 1514 E Union St, Greenville, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922072891 | NPI | - | NPPES |
| 00123081 | Medicaid | MS | |
| 129581001 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 16611 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Delta Regional Medical Center Hospice | Greenville, MS | Hospice |
| Delta Regional Medical Center | Greenville, MS | Hospital |
| Bolivar Medical Center | Cleveland, MS | Hospital |
| West Carroll Memorial Hospital | Oak grove, LA | Hospital |
| South Sunflower County Hospital | Indianola, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Delta Health-the Medical Center | 0042208787 | 2 |
| Delta Medical Group | 6608775531 | 37 |
News Archive
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009.
More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
New blood-testing technology that promises to improve healthcare treatments for cancer patients, post-operative care and monitor the health of babies in the womb is being developed by Lancaster academics.
› Verified 1 days ago
| Entity Name | Delta Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790701134 PECOS PAC ID: 6608775531 Enrollment ID: O20040108000636 |
News Archive
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009.
More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
New blood-testing technology that promises to improve healthcare treatments for cancer patients, post-operative care and monitor the health of babies in the womb is being developed by Lancaster academics.
› Verified 1 days ago
| Entity Name | Delta Health-the Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083764542 PECOS PAC ID: 0042208787 Enrollment ID: O20040503000961 |
News Archive
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009.
More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
New blood-testing technology that promises to improve healthcare treatments for cancer patients, post-operative care and monitor the health of babies in the womb is being developed by Lancaster academics.
› Verified 1 days ago
| Entity Name | Medical Oncology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629044839 PECOS PAC ID: 3173509338 Enrollment ID: O20040628000975 |
News Archive
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009.
More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
New blood-testing technology that promises to improve healthcare treatments for cancer patients, post-operative care and monitor the health of babies in the womb is being developed by Lancaster academics.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maroun E Hayek, MD 1514 E Union St, Greenville, MS 38703-3248 Ph: (662) 334-6394 | Maroun E Hayek, MD 1514 E Union St, Greenville, MS 38703-3248 Ph: (662) 334-6394 |
News Archive
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009.
More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, according to research published in the Journal of Clinical Oncology.
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
New blood-testing technology that promises to improve healthcare treatments for cancer patients, post-operative care and monitor the health of babies in the womb is being developed by Lancaster academics.
› Verified 1 days ago
Nouhad O Kronfol, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1997 Medical Park Dr, Greenville, MS 38703 Phone: 662-335-4105 Fax: 662-378-2879 | |
Deepali Ramdas Kale, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 344 Arnold Ave, Greenville, MS 38701 Phone: 662-378-1311 Fax: 662-335-2001 | |
John L Herzog Sr., MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1421 E Union St, Greenville, MS 38703 Phone: 662-335-0183 Fax: 662-335-7184 | |
J Barry Gillespie, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1502 S Colorado St, Greenville, MS 38703 Phone: 662-332-9872 Fax: 662-378-0280 | |
Dr. Wilson M Parry, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1502 S Colorado St, Greenville, MS 38703 Phone: 662-335-4105 Fax: 662-378-2879 | |
Ravi V Patel, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1502 S Colorado St, Greenville, MS 38703 Phone: 662-335-4105 | |
Dr. Jerry Milton Cunningham, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 521 Fairview, Greenville, MS 38701 Phone: 662-334-9182 Fax: 662-335-5320 |